DUBLIN, March 22, 2023 /PRNewswire/ — The “Diabetes Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030” report has been added to ResearchAndMarkets.com’s offering. This research study…
Month: March 2023
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Ryvyl Inc. (“Ryvyl” or the “Company”) (NASDAQ: RVYL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation…
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation…
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) (“Adagio” or the “Company”) (NASDAQ: IVVD; ADGI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or…
AUSTIN, Texas, March 22, 2023 /PRNewswire/ — Texas Medical Liability Trust, on behalf of itself and its affiliates, Texas Medical Insurance Company, Physicians Insurance Company, and Lone Star Alliance Inc., a Risk Retention Group (collectively “TMLT”) is providing notice of a recent…
NEW YORK, March 22, 2023 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of VBit Technologies Corp., VBit Mining LLC (Collectively, “VBit”) securities, which were unregistered in the form of investment contracts, between January 1, 2019 and…
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Granite Ridge Resources, Inc. (“Granite Ridge” or the “Company”) (NYSE: GRNT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext….
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980….
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Fox Corporation (“Fox” or the “Company”) (NASDAQ: FOX; FOXA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The…
NEW YORK, March 22, 2023 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of SVB Financial Group (“SVB” or the “Company”) (NASDAQ: SIVB). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The…